Atriva Therapeutics GmbH, corporate

Atriva Therapeutics GmbH,

09.11.2021 - 09:03:52

Atriva Therapeutics' lead candidate Zapnometinib shows substantial efficacy against SARS-CoV-2

or respiratory syncytial virus (RSV)[2] and also coronaviruses[2], thereof SARS-CoV-2. Zapnometinib inhibits the cellular MEK (MAPK/ERK kinase), blocking the formation of functional virus particles in the host cell, ultimately reducing the viral load in the body.[3],[4] The specific mode of action varies depending on the actual virus type. E.g., in influenza virus infected cells, MEK inhibition blocks the export of the viral genome protein complexes (ribonucleoprotein, RNP) from the nucleus to the cytoplasm.[1]

In addition, zapnometinib has the potential to modulate the immune response of the body, among others avoiding overshooting cytokine/chemokine response that can be caused by such viral infections. MEK inhibition can reduce the gene expression of some of the cytokines/chemokines involved, like TNF-?, IL-1?, IP-10, IL-8, MCP-1 and MIP-1a,[5],[6] and thus mitigate the overactive inflammatory response in the lungs of patients who are severely ill with influenza or COVID-19.[7]

About Atriva Therapeutics GmbH

Atriva Therapeutics, founded in 2015, is a biopharmaceutical company that is pioneering the development of host-targeting antiviral therapies. It was set up by a team of leading scientists in viral research as well as proven industry experts. The company aims to develop a therapy platform to treat severe respiratory diseases induced by RNA viruses with a high unmet medical need, such as influenza and COVID-19. The Atriva lead product zapnometinib (pINN, currently known as ATR-002) is a first-in-class, host-targeting agent that aims to inhibit viral replication and to favorably modulate the body's immune response in such RNA viruses. Zapnometinib is under clinical development and has successfully completed a Phase I trial to demonstrate safety and tolerability in healthy subjects. The Company is actively enrolling patients in a Phase II study to evaluate efficacy in hospitalized COVID-19 patients.[8] A Phase II study in influenza is currently planned, as are further Phase II and III studies in COVID-19. The Company owns 11 patent families with broad international coverage related to the use of MEK inhibitors and other kinase inhibitors for antiviral therapies. The patent life runs through 2041. Atriva Therapeutics is based in T?bingen and Frankfurt, Germany.

Atriva is a founding member of the BEAT-COV initiative. www.beat-cov.de

For further information, please visit www.atriva-therapeutics.com and follow us on LinkedIn and Twitter.

About Viroclinics-DDL

Viroclinics-DDL is a leading specialty contract research organization, serving the biopharmaceutical community with a broad range of preclinical research, clinical diagnostic, assay development, laboratory and clinical trial logistic services. It offers its clients a global reach through a network of 35 processing laboratories. Viroclinics-DDL extensive experience in clinical and preclinical studies for viruses, including its specialty in respiratory and blood-borne viruses, puts the company at the forefront in supporting the development of vaccines, antibodies and antiviral compounds targeting viral infectious diseases. Its in-house state-of-the-art preclinical and clinical BSL-2 and BSL-3 laboratories facilitate complex experiments with highly pathogenic organisms. Viroclinics-DDL is based in Rotterdam, Rijswijk and Schaijk in the Netherlands, and employs more than 350 highly-trained, dedicated scientists and technical experts. For more information, visit www.viroclinics.com and www.ddl.nl

Contact: Atriva Therapeutics GmbH Dr. Rainer Lichtenberger, CEO phone: +49 69 667781 5180 mobile: +49 151 7443 3175lichtenberger@atriva-therapeutics.com? ?Viroclinics-DDL Sander Verkerk Manager Marketing & Communications Tel: +31 88 668 4787marketing@viroclinics.com Media and Investor Relations: MC Services AG Eva Bauer / Raimund Gabriel phone: +49 89 210 228 80atriva-therapeutics@mc-services.eu ?

References:[1]Pleschka S et al. Nat Cell Biol 2001; 3:301-5[2]Pleschka S, Biol. Chem. 2008; 389:1273-1282[3]Haasbach E et al. Antiviral Res 2017; 142:178-4[4]Laure M et al. Antiviral Res 2020; 178:104806[5]Planz O Antiviral Res 2013; 98:457-68[6]Pinto R et al. Antiviral Res 2011; 92:45-56[7]Ragab D et al., Front Immunol 2020; 11: 1446[8]RESPIRE - A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients with COVID-19.

09.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at www.dgap.de

1247141??09.11.2021?

@ dgap.de